Posted by Michael Wonder on 12 May 2023
PBAC backs ongoing access to low-dose asthma puffer for Aussie kids
12 May 2023 - The independent, expert group advising the Australian Government on PBS medications has reviewed its recommendation to put tighter controls around an important asthma medication for children.
The PBAC had previously recommended 50 mcg/dose Axotide Junior and Flixotide Junior (fluticasone propionate) be:
- restricted to children aged 6 years and under
- be initially prescribed by a respiratory specialist
- only prescribed with authority approval by Medicare
These changes were made to the PBS on 1 April 2023.
